Non-cirrhotic portal hypertension in HIV-infected individuals

International Journal of STD and AIDS

Volumn 22, Issue 6, 2011, Pages 324-328

  Scourfield, A ^a   Waters, L ^a   Holmes, P ^a   Panos, G ^a   Randell, P ^a   Jackson, A ^a   Mandalia, S ^b   Gazzard, B ^a   Nelson, M ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Didanosine; HIV; Liver; Nodular regenerative hyperplasia; Portal hypertension; Pulmonary hypertension

Indexed keywords

ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; BLOOD CLOTTING; DEVICE; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ELASTOGRAPHY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON CIRRHOTIC PORTAL HYPERTENSION; PORTAL HYPERTENSION; PRIORITY JOURNAL; REVIEW; UPPER GASTROINTESTINAL BLEEDING;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DIDANOSINE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HIV INFECTIONS; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 79959509341     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2010.010396     Document Type: Review

References (28)

1. Maida I, Nunez M, Jose Rios M, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006;42:177-82
2. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 2001;35:195-9
3. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-7
4. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23
5. Merriman RB. Nonalcoholic fatty liver disease and HIV infection. Curr HIV/AIDS Rep 2006;3:113-7
6. Kovari H, Ledergerber B, Peter U, et al. Swiss HIV Cohort Study. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009;49:626-35
7. Schiano TD, Kotler DP, Ferran E, Fiel MI. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2007;102:2536-40
8. Mallet V, Blanchard P, Verkarre V, et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007;21:187-92
9. Saifee S, Joelson D, Braude J, et al. Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection. Clin Gastroenterol Hepatol 2008;6:1167-9
10. Maida I, Garcia-Gasco P, Sotgiu G, et al. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther 2008;13:103-7
11. Garvey LJ, Thomson EC, Lloyd J, et al. Response to Mallet et al., 'Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients'. AIDS 2007;21:1494-5
12. See http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/ucm199169.htm (last accessed 21 September 2010)
13. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30:1054-8
14. Estes J, Baker JV, Brenchley JM, et al. Collagen deposition limits immune reconstitution in the gut. J Infect Dis 2008;198:456-64
15. Grunfeld C, Delaney JA, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009;23:1841-9
16. Nies-Kraske E, Schacker TW, Condoluci D, et al. Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy. J Infect Dis 2009;199:1648-56
17. Mallet VO, Varthaman A, Lasne D, et al. Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. AIDS 2009;23:1511-8
18. Cesari M, Schiavini M, Marchetti G, et al. Noncirrhotic portal hypertension in HIV-infected patients: a case control evaluation and review of the literature. AIDS Patient Care STDS 2010;24:697-703
19. Sitbon O. HIV-related pulmonary arterial hypertension: clinical presentation and management. AIDS 2008;22(Suppl 3):S55-62
20. Price DA, Schmid ML, Ong EL, Adjukeiwicz KM, Peaston B, Snow MH. Pancreatic exocrine insufficiency in HIV-positive patients. HIV Med 2005;6:33-6
21. Bureau C, Metivier S, Peron JM, et al. Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease. Aliment Pharmacol Ther 2008;27:1261-8
22. Merchante N, Pérez-Camacho I, Mira JA, et al. Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine. Antivir Ther 2010;15:753-63
23. Thomson EC, Nastouli E, Main J, et al. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS 2009;23:89-93
24. Ingiliz P, Valantin MA, Duvivier C, et al. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 2009;49:436-42
25. Chariot P, Drogou I, de Lacroix-Szmania I, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 1999;30:156-60
26. Vittecoq D, Jardel C, Barthélémy C, et al. Mitochondrial damage associated with long-term antiretroviral treatment: associated alteration or causal disorder? J Acquir Immune Defic Syndr 2002;31:299-308
27. Tateo M, Sebagh M, Bralet MP, et al. A new indication for liver transplantation: nodular regenerative hyperplasia in human immunodeficiency virus-infected patients. Liver Transpl 2008;14:1194-8
28. D:A:D Study Group. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. J Infect Dis 2010;201:318-30